ClinicalTrials.gg
CompletedNCT04665284SAFE-PAKUpdated Dec 11, 2020

Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

A Phase 4 interventional study of Empagliflozin and Usual care group in Type II Diabetes Mellitus, sponsored by Getz Pharma. Completed at 11 sites in Pakistan. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-11.

Sponsored by Getz Pharma · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jun 2019, registered Nov 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
32nd of 130
244 · median 79
Started
2019
with 5 others
Phase 4
50 of 130
11 open now
Registered
83rd of 130
by date
Lead sponsor
4 of 130
Getz Pharma

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 32nd largest by enrollment, is one of 6 that started in 2019, is one of 50 in phase 4, and was the 83rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To compare the safety and efficacy of empagliflozin versus other treatments in Pakistani Muslim population with type II diabetes mellitus.

Read the detailed description

Diabetes is the one of the most common non-communicable diseases affecting 425 million adults worldwide. This figure is expected to rise to 629 million by the year 2045.1 90% of the diabetic population has type 2 diabetes. 2 As of 2018, more than 500 million individuals are residing with type 2 diabetes mellitus globally. 3 In Pakistan, the situation is similarly alarming. According to a recent survey, 16.98% of the Pakistani population has diabetes.4 The primary target of therapy in diabetes mellitus is optimum blood glucose control. In case of type 2 diabetes, this is achieved by a combination of oral hypoglycemic agents and injectable drugs with insulin as a last resort.

A number of oral agents targeting various sites of action are available. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are newer class of drugs that have been introduced. They have a unique mechanism of action. By acting at the sodium glucose co-transporter, they block the reabsorption of glucose leading to an increase in urinary glucose excretion and lowering of plasma glucose.5 This action is completely independent of the beta cell function. There are several theoretical advantages to this approach. In addition to lowering blood glucose, the urinary glucose excretion results in loss of calories and weight reduction and the associated osmotic diuretic effect can aid in lowering blood pressures.6,7 Numerous studies have demonstrated a favorable risk benefit ratio of empagliflozin as monotherapy8 as well as add-on therapy to other hypoglycemic agents.9,10,11,12 They also have additional cardiovascular benefits with several studies documenting a reduction in mortality.13,14 Moreover, the sodium glucose co-transporters also demonstrated a reduction in the onset and worsening of nephropathy and preservation of renal function.15 This effect is not restricted to empagliflozin alone, as other drugs in the class have also demonstrated this benefit.16 Empagliflozin with its novel mechanism of action has its own set of side effects. Increased urinary glucose losses lead to a higher proportion of urinary tract infections and genital tract infections. This has been evidenced in various studies.17 The osmotic diuresis that benefits in lowering blood pressures at one end, also predisposes the patients to volume depletion.Empagliflozin, one of the three drugs from this class, approved by the FDA for treatment of type 2 diabetes. According to the recent ADA and the EASD guidelines, they have become an essential component of the algorithm recommended for managing type 2 diabetes.18 The recently published consensus statement by the South Asian Federation of Endocrine Societies has incorporated sodium glucose co-transporter 2 inhibitors in the treatment of patients with type 2 diabetes as monotherapy in patients who are intolerant to or have any contraindication to metformin therapy. Additionally, drugs belonging to this class are also recommended as combination therapy with other oral hypoglycemic agents as well as insulin.19 Empagliflozin, however, has not been studied in the Pakistani population as yet. The main aim of this study is to establish the efficacy and safety of empagliflozin in optimum control of blood sugar in type 2 diabetes. This is the first study of its kind being performed in the Pakistani population.

03

Conditions studied

  • Type II Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pakistani muslim male / female, type 2 diabetic patient having age from 18 years to 75 years
  • Patient who give voluntarily
  • ≤45 kg/m2
  • Glycosylated of 7 - ≤10%

Exclusion criteria

Exclusion Criteria:

  • Patients who are on empagliflozin treatment
  • Indication of liver disease, defined by serum levels of either , aspartate aminotransferase, and alkaline phosphatase above 3 times upper limit to normal
  • Estimated (eGFR) \<45 mL /min /1.73m2
  • History of recurrent urinary tract infection (UTI) and/or past 3 months' history of UTI and its treatment
  • Patients with positive urine culture for UTI at the time of screening
  • Patients who have been admitted to the hospital in the past 3 months for diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state
  • Patients with past 3 months' history of fungal infection and its treatment
  • History of blood dyscrasias or any disorders causing haemolysis or unstable red blood cell
  • History of benign prostate hyperplasia
  • Any acute coronary syndrome, stroke and/or (TIA) in the previous 3 months
  • Any for patients to Biguanides, Sulfonylureas, DPP-IV inhibitors, SGLT-2 Inhibitors
  • Treatment with anti-obesity drugs or any other treatment leading to unstable body weight
  • Patients with past 6 weeks treatment history with systemic or thyroid hormones or any other uncontrolled endocrine disorder except T2DM
  • Pre-menopausal women who are nursing or pregnant or are of and not practicing an acceptable method of
  • Any other clinical condition that would jeopardize patients safety while participating in this study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
244 participants (actual)

Study arms

  • Experimental
    Empagliflozin

    Drug: Empagliflozin

  • Active comparator
    Usual Care Group

    Drug: Usual care group

Interventions

  • Group A: Empagliflozin 10/25 mg once daily with or without antidiabetic drugs

    Also known as: Group A

  • DrugUsual care group

    Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care

    Also known as: Group B

06

What researchers measure

Primary outcomes

  1. Number of participants reported adverse events

    Number of participants reported adverse events such as Hypoglycemic events, Hypotension, Dehydration, Urinary tract infection, Diabetic Ketoacidosis, Fungal infection or any other

    Time frame: 24 weeks

Secondary outcomes

  1. Frequency of participants achieved HbA1c level <7%

    Frequency of participants achieved HbA1c level \<7%

    Time frame: 24 weeks

  2. Frequency of participants achieved FBS level within normal range

    Frequency of participants achieved FBS level within normal range

    Time frame: 24 weeks

Other outcomes

  1. Number of participants reduces weight during the therapy

    Number of participants reduces weight during the therapy or mean reduction in weight overtime

    Time frame: 24 weeks

  2. Number of participants reduces BMI level as per WHO Asian classification during the therapy

    Number of participants reduces BMI or mean reduction in BMI overtime

    Time frame: 24 weeks

  3. Number of participants reduces Waist circumference during the therapy

    Number of participants reduces Waist circumference or mean reduction in BMI overtime

    Time frame: 24 weeks

  4. Number of participants changes systolic blood pressure and diastolic blood pressure during the therapy

    Number of participants reduces systolic blood pressure and diastolic blood pressure or mean reduction in systolic blood pressure and diastolic blood pressure overtime

    Time frame: 24 weeks

  5. Number of participants changes LDL level and HDL Level during the therapy

    Number of participants reduces LDL level and HDL Level or mean reduction in LDL level and HDL Level overtime

    Time frame: 24 weeks

  6. Mean score of diabetes mellitus quality of life

    The instrument provides an overall scale score, as well as two subscale scores for 1) satisfaction with treatment, 2) adherence with Self Care Regimen. 15 Items are scored on a 5-point Likert scale and are of two general formats.One format asks about the frequency of negative impact of diabetes itself or of the diabetes treatment and provides response options from 1 (never) to 5 (all the time). The second format asks about satisfaction with treatment and quality of life and is scored from 1 (very satisfied) to 5 (very dissatisfied). Higher scores on DQOL items and subscales are, therefore, negatively valenced, indicating problem frequency or dissatisfaction.

    Time frame: 24 weeks

07

Study locations

11 sites
  • Balochistan Medical Center
    Quetta, Balochistan, Pakistan
  • Lady Reading Hospital
    Peshawar, Khyber Pakhtunkhwa, Pakistan
  • Post Graduate Medical Institute
    Peshawar, Khyber Pakhtunkhwa, Pakistan
  • Hanif Medical Center
    Islamabad, Punjab, Pakistan
  • Shifa International Hospital
    Islamabad, Punjab, Pakistan
  • Diabetes Institute of Pakistan
    Lahore, Punjab, Pakistan
  • Jinnah Hospital
    Lahore, Punjab, Pakistan
  • National Defence Center
    Lahore, Punjab, Pakistan
  • Al-Khaliq Hospital
    Multān, Punjab, Pakistan
  • Fatimiyah Hospital
    Karachi, Sindh, Pakistan
  • National Institute of Cardiovascular Disease
    Karachi, Sindh, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Sep 2020, 15 months.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 15 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2020
First posted
Dec 11, 2020
StartActual
Jun 1, 2019
Primary completionActual
Sep 15, 2020
CompletionActual
Sep 28, 2020
Last update
Dec 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04665284
Lead sponsor
Getz Pharma
Responsible party
Sponsor
First posted
Dec 11, 2020
Start date
Jun 1, 2019
Primary completion
Sep 15, 2020
Completion
Sep 28, 2020
Last update
Dec 11, 2020

Study contacts

A H Aamir
principal investigator · Post Graduate Medical Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion